PhRMApedia Press Room
PhRMApedia's Press Room will provide the most recent press releases. Search PhRMApedia for additional press releases. PhRMApedia is your new resource hub. You can search our entire database of media releases, reports, white papers, videos and more. Type your keywords in the search bar and explore PhRMA’s resources. Search results will appear by type, title and date.
PhRMA member companies invested an estimated $51.2 billion last year in the research and development (R&D) of new innovative treatments and cures. The figure represents the majority of all biopharmaceutical R&D spending – both public and private – in the United States.
Award Honors Extraordinary Efforts in Policy Advocacy and Community Service
Washington, D.C. (April 17, 2015) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) honored 13 employees from 12 biopharmaceutical companies as “We Work For Health Champions” for their extraordinary efforts in policy advocacy and community service.
Biogen CEO George A. Scangos and Johnson & Johnson Worldwide Chairman for Pharmaceuticals Joaquin Duato Assume New Posts ; Castellani Announces Retirement
Washington, D.C. (April 16, 2015) — Today, Kenneth C. Frazier, chairman and chief executive officer (CEO) of Merck & Co., Inc., was elected chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). At today’s Board meeting, PhRMA’s president and CEO John J. Castellani announced that he will be retiring effective January 1, 2016.
New Officers Elected to PhRMA Board
Washington, D.C. (April 15, 2015) — The Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation has awarded four research grants as part of its Young Investigator Adherence Grant Program.
Established in 2012, the Young Investigator Adherence Grant Program was created by the PhRMA Foundation to support research conducted by predoctoral candidates, postdoctoral fellows, and junior faculty to advance knowledge of innovative and effective approaches to improve medication adherence.
Washington, D.C. (April 7, 2015) —The Partnership for Prescription Assistance (PPA), a program sponsored by America’s biopharmaceutical research companies to connect uninsured or underinsured Americans to programs that provide prescription medicines for free or nearly free, is celebrating its 10th anniversary this week. Since the program’s launch in April 2005, PPA has connected nearly 9.5 million Americans to public and private assistance programs.
Despite more Americans having insurance, barriers to accessing needed medicines still exist, underscoring the importance of PPA’s platform to educate and empower patients and caregivers to obtain information about their prescription assistance options.
PhRMA supports a science-based, transparent implementation of the BPCIA biosimilars pathway.
Washington, D.C. (March 3, 2015) — Today, the Partnership for Prescription Assistance (PPA), a nationwide effort sponsored by America’s biopharmaceutical research companies, unveiled a redesigned website with new features and functionality to provide patients and caregivers with faster, easier access to information on more than 475 public and private patient assistance programs.
Visit www.FromHopetoCures.org to learn more about the value medicines provide to patients, society and our economy
Washington, D.C. – Patients and scientists from across the country are featured in the latest “From Hope to Cures” ad campaign launched today by the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading biopharmaceutical researchers and biotechnology companies.
Washington, D.C. (February 25, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President of Scientific and Regulatory Affairs Dr. Bill Chin issued the following statement today in support of legislation to prevent sequestration of prescription drug user fees:
“PhRMA strongly supports the FDA Safety Over Sequestration Act, which would exempt future Food and Drug Administration’s (FDA) user fees from sequestration. We commend Representatives Leonard Lance (R-NJ) and Anna Eshoo (D-CA) for their continued leadership on this critical issue.
Washington, D.C. (February 25, 2015) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
Washington, D.C. (February 24, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) assistant general counsel, John Murphy, issued the following statement regarding a federal court ruling that invalidated an importation law in Maine.
Washington, D.C. (February 12, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) executive vice president, Lori Reilly, issued the following statement on the Center for Medicare & Medicaid Innovation’s (CMMI) announcement of its Oncology Care Model demonstration program, which will test a new approach for paying doctors for their care of cancer patients:
Washington, D.C. (January 21, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO, John J. Castellani released the following statement:
Washington, D.C. (February 5, 2015) — The following statement is provided by Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO, John J. Castellani:
“We thank Chairman Goodlatte for his leadership in the effort to curb abusive practices that can arise in patent litigation and enforcement. We look forward to reviewing this proposal and working with Congress to ensure legislation addressing patent litigation is not harmful to the patent system.
Washington, D.C. (February 5, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and Chief Executive Officer, John Castellani, provided the following statement:
“PhRMA salutes the work of Commissioner Hamburg and recognizes her significant contributions to the thoughtful regulation of medicines, including science as a basis for better regulatory decisions. For nearly six years, and to the direct benefit of patients, Commissioner Hamburg has demonstrated strong leadership and an unwavering commitment to collaboration with all stakeholders.
“We look forward to working with the FDA’s leadership and Acting Commissioner Ostroff to bring safe and effective innovative medicines to patients.”